% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Jones:124366,
      author       = {C. Jones and M. A. Karajannis and D. Jones$^*$ and M. W.
                      Kieran and M. Monje and S. J. Baker and O. J. Becher and
                      Y.-J. Cho and N. Gupta and C. Hawkins and D. Hargrave and D.
                      A. Haas-Kogan and N. Jabado and X.-N. Li and S. Mueller and
                      T. Nicolaides and R. J. Packer and A. I. Persson and J. J.
                      Phillips and E. F. Simonds and J. M. Stafford and Y. Tang
                      and S. Pfister$^*$ and W. A. Weiss},
      title        = {{P}ediatric high-grade glioma: biologically and clinically
                      in need of new thinking.},
      journal      = {Neuro-Oncology},
      volume       = {19},
      number       = {2},
      issn         = {1523-5866},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2017-01245},
      pages        = {153-161},
      year         = {2017},
      abstract     = {High-grade gliomas in children are different from those
                      that arise in adults. Recent collaborative molecular
                      analyses of these rare cancers have revealed previously
                      unappreciated connections among chromatin regulation,
                      developmental signaling, and tumorigenesis. As we begin to
                      unravel the unique developmental origins and distinct
                      biological drivers of this heterogeneous group of tumors,
                      clinical trials need to keep pace. It is important to avoid
                      therapeutic strategies developed purely using data obtained
                      from studies on adult glioblastoma. This approach has
                      resulted in repetitive trials and ineffective treatments
                      being applied to these children, with limited improvement in
                      clinical outcome. The authors of this perspective,
                      comprising biology and clinical expertise in the disease,
                      recently convened to discuss the most effective ways to
                      translate the emerging molecular insights into patient
                      benefit. This article reviews our current understanding of
                      pediatric high-grade glioma and suggests approaches for
                      innovative clinical management.},
      subtyp        = {Review Article},
      cin          = {B062},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27282398},
      pmc          = {pmc:PMC5464243},
      doi          = {10.1093/neuonc/now101},
      url          = {https://inrepo02.dkfz.de/record/124366},
}